Compare CVS Health Corp (CVS) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Charles Schwab Corporation Common Stock — how do they compare? CVS Health Corp trades at $104.01 (market cap $135.48B), while Charles Schwab Corporation Common Stock trades at $101.2 (market cap $175.83B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | SCHW | |
|---|---|---|
Market Cap | $135.48B | $175.83B |
Sector | Health | Financials |
52-Week High | $106.18 | $107.21 |
52-Week Low | $58.75 | $85.35 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Charles Schwab (SCHW) trades at $102.38, down 0.72% on the day, with a bullish technical outlook and strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.43 versus $1.40 expected, highlight robust profitability. The stock is supported by a 21.79% ROE and a net income margin of 37.99%, with revenue growth to $23.92 billion in 2025. Positive sentiment is fueled by a Zacks Strong Buy upgrade and a consensus price target of $122.71, suggesting 20% upside.
Outlook remains favorable given earnings momentum and retail trading growth, but risks include interest rate sensitivity and competitive pressures. Analyst consensus is 58% buy, with institutional confidence bolstered by a recent dividend payment. The stock's valuation at a P/E of 20.35 appears reasonable relative to growth, though high RSI levels indicate potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
